Market closed
CureVac/$CVAC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About CureVac
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Ticker
$CVAC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,086
Website
CureVac Metrics
BasicAdvanced
$718M
Market cap
-
P/E ratio
-$1.30
EPS
2.59
Beta
-
Dividend rate
Price and volume
Market cap
$718M
Beta
2.59
52-week high
$6.30
52-week low
$2.22
Average daily volume
584K
Financial strength
Current ratio
2.287
Quick ratio
2.194
Long term debt to equity
9.02
Total debt to equity
10.367
Management effectiveness
Return on assets (TTM)
-24.52%
Return on equity (TTM)
-54.30%
Valuation
Price to revenue (TTM)
10.408
Price to book
1.91
Price to tangible book (TTM)
2.05
Price to free cash flow (TTM)
-2.076
Growth
Revenue change (TTM)
75.11%
Earnings per share change (TTM)
-15.72%
3-year revenue growth (CAGR)
14.71%
3-year earnings per share growth (CAGR)
-15.34%
What the Analysts think about CureVac
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for CureVac stock.
CureVac Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CureVac Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CureVac News
AllArticlesVideos
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Accesswire·1 month ago
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for CureVac stock?
CureVac (CVAC) has a market cap of $718M as of December 14, 2024.
What is the P/E ratio for CureVac stock?
The price to earnings (P/E) ratio for CureVac (CVAC) stock is 0 as of December 14, 2024.
Does CureVac stock pay dividends?
No, CureVac (CVAC) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next CureVac dividend payment date?
CureVac (CVAC) stock does not pay dividends to its shareholders.
What is the beta indicator for CureVac?
CureVac (CVAC) has a beta rating of 2.59. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.